Last reviewed · How we verify
P-GEMD
P-GEMD is a small molecule that targets the molecular target.
P-GEMD is a small molecule that targets the molecular target. Used for Atrial fibrillation for stroke prevention.
At a glance
| Generic name | P-GEMD |
|---|---|
| Sponsor | The First Affiliated Hospital with Nanjing Medical University |
| Drug class | small molecule |
| Target | unknown |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
P-GEMD works by binding to the molecular target, which leads to a specific therapeutic effect.
Approved indications
- Atrial fibrillation for stroke prevention
Common side effects
- Headache
- Nausea
- Dizziness
Key clinical trials
- A Study Comparing of P-GEMD Regimen Versus P-Gemox Regimen With Untreated Early-Stage NUAT or Advanced-Stage ENKTL. (PHASE3)
- Pegaspargase Combined With Gemcitabine, Etoposide, Liposomal Mitoxantrone Hydrochloride and Dexamethasone (P-GEMD) in the Treatment of Untreated Early Non-upper Respiratory Tract or Advanced Extranodal NK/T-cell Lymphoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- P-GEMD CI brief — competitive landscape report
- P-GEMD updates RSS · CI watch RSS
- The First Affiliated Hospital with Nanjing Medical University portfolio CI